July 22, 2020     LifeOS Genomics, a biotech company focusing on multiplex digital PCR (mdPCR) genetic testing platform and related application products, announces the commercial research-use-only (RUO) release of QLoci™ Automated Multiplex Digital PCR (mdPCR™) System, during 2020 BioAsia – Taiwan International Conference and Exhibition. QLoci™ Automated Multiplex Digital PCR (mdPCR™) System includes fully automated md1000 Analyzer, related consumables, system reagents, and QLoci™ Application Development Kit (ADK).

The released products are based on LifeOS Genomics proprietary multiplex digital PCR (mdPCR™) technology, a breakthrough of digital PCR, and are intended for users in academic and clinical research, as well as genetic testing service providers. It can achieve multiplexed quantitative analysis of up to 100 genetic biomarkers in a single assay with the sensitivity and accuracy of digital PCR method. Its automated analysis process enables a wide range of applications in genetic testing, such as precision medicine, early disease diagnosis, prenatal screening, and infectious pathogen identification, especially for distributed test centers and hospitals. QLoci™ ADK allows users to develop their own customized applications on LifeOS Genomics mdPCR™ system.

LifeOS Genomics exhibition booth in 2020 BioAsia – Taiwan International Conference and Exhibition is at Booth S709.

About LifeOS Genomics:   LifeOS Genomics, located in Hsinchu City, Taiwan, is a biotechnology and in-vitro diagnostics company focusing on IVD genetic testing products for liquid biopsy. LifeOS Genomics’ flagship product, the QLoci™ Automated Multiplex Digital PCR (mdPCR™) System, is an automated genetic testing platform based on our innovative mdPCR™ technology. By leveraging the unique high multiplexity and sensitivity of this PCR technology, LifeOS aims for decentralized routine genetic testing in healthcare industry. www.lifeosgenomics.com